Press release

DSM and Groupe Sebbin partner to provide treatment options for breast reconstruction and aesthetic plastic surgery

Exton PA, US, 10 Dec 2014 16:00 CET

Groupe Sebbin will distribute DSM’s Meso BioMatrix® Acellular Peritoneum Matrix in Europe and Latin America

DSM, a global leader in biomedical materials science and regenerative medicine, today announced a long-term partnership with Groupe Sebbin, a leading manufacturer of breast implants for plastic and reconstructive surgery. Groupe Sebbin will market and distribute DSM’s Meso BioMatrix® Acellular Peritoneum Matrix in Europe and Latin America.

The Meso BioMatrix Acellular Peritoneum Matrix is the newest addition to a family of extracellular matrix devices processed using DSM’s proprietary OPTRIX™ manufacturing process. There are estimated to be more than 1.7 million new cases of breast cancer reported each year throughout the world. With the increased attention on therapeutic and preventative treatments, as well as recent advance in surgical intervention procedures for managing breast cancer, many women are being offered and opting for breast reconstruction as an aid to restoring a sense of well-being. Designed and developed by DSM, the Meso BioMatrix Acellular Peritoneum Matrix is a surgical mesh that provides easy handling for surgeons with the strength necessary to reinforce soft tissue in breast reconstruction procedures.

“This partnership represents an important milestone as DSM continues its mission to be a developer of innovative regenerative medicine technologies,” said Scott Goldman, Innovation Director, Natural Materials, DSM Biomedical. “We look forward to building upon our newly formed relationship with Sebbin, a highly respected leader in the breast reconstruction industry.”

Sebbin welcomes the opportunity to partner with DSM and to support the use of natural materials in reconstructive and plastic surgeries,” said Diederik Van Goor, Chief Operation Officer, Groupe Sebbin. “This partnership adds an important technology into our product portfolio and will allow us to offer an even greater range of technologies dedicated to breast reconstruction.”

Groupe Sebbin will showcase the Meso BioMatrix Acellular Peritoneum Matrix product in Paris at the 59th National Congress of the French Society of Plastic, Aesthetic and Reconstructive Surgery (SOF.CPRE), 11–13 December 2014.

For more information about DSM’s Meso BioMatrix Acellular Peritoneum Matrix please visit: Meso BioMatrix surgical mesh.

For more information

Kwittken & Company

+1 646 747 7161

Read more

  • Our products

    Our products

    DSM portfolio of innovative biomedical materials and process manufacturing technologies: Biomedical Polyethylenes, Biomedical polyurethanes, Collagen Technology, Device Development, and Extracellular Matrix (ECM) Technology. Learn more.

  • The markets we serve

    The markets we serve

    DSM Biomedical offers the broadest portfolio of biomedical materials and manufacturing across market applications, including orthopedics, ophthalmology, neurology, cardiology, diabetes, wound, and continence care.

This site uses cookies to store information on your computer.

Learn more